Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp

Phytotherapy Research

Volumn 23, Issue 11, 2009, Pages 1553-1558

  Qiu, W ^a,b   Jiang, X H ^a   Liu, C X ^c   Ju, Y ^b   Jin, J X ^b  

^a SICHUAN UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Berberine; Carbamazepine; Cyclosporine A; CYP3A; Digoxin; P glycoprotein

Indexed keywords

BERBERINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYCLOSPORIN A; CYTOCHROME P450 3A; DIGOXIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT;

ANIMALS; AREA UNDER CURVE; BERBERINE; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DIGOXIN; DRUG INTERACTIONS; MALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR;

RATTUS;

EID: 70350437674     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2808     Document Type: Article

References (21)

1. Chatterjee P, Franklin MR. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31: 1391-1397. (Pubitemid 37310329)
2. Christians U, Strohmeyer S, Kownatzki R et al. 1991. Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile - isolation of 12 new cyclosporine metabolites. Xenobiotica 21: 1185-1198.
3. Ckless K, Schlottfeldt JL, Pasqual M, Moyna P, Henriques JA, Wajner M. 1995. Inhibition of in vitro lymphocyte transformation by the isoquinoline alkaloid berberine. J Pharm Pharmacol 47: 1029-1031. (Pubitemid 26048174)
4. He L, Liu GQ. 2002. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin 23: 591-596. (Pubitemid 34733319)
5. Hori R, Okamura N, Aiba T, Tanigawara Y. 1993. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266: 1620-1625. (Pubitemid 24175813)
6. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. 1998. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc Natl Acad Sci USA 95: 6602-6606. (Pubitemid 28278026)
7. Iizuka N, Miyamoto K, Okita K et al. 2000. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 148: 19-25. (Pubitemid 30012124)
8. Kaneda Y, Torii M, Tanaka T, Aikawa M. 1991. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. Ann Trop Med Parasitol 85: 417-425.
9. Kerr BM, Thummel KE, Wurden CJ et al. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47: 1967-1979.
10. Lertratanangkoon K, Horning MG. 1982. Metabolism of carbamazepine. Drug Metab Dispos 10: 1-10.
11. Lewis K. 1999. Multidrug resistance: versatile drug sensors of bacterial cells. Curr Biol 9: R403-R407. (Pubitemid 29273098)
12. Lin HL, Liu TY, Lui WY, Chi CW. 1999a. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 85: 1937-1942.
13. Lin HL, Liu TY, Wu CW, Chi CW. 1999b. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to paclitaxel. Br J Cancer 81: 416-422.
14. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. 2001. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21: 778-796.
15. Panesar SK, Bandiera SM, Abbott FS. 1996. Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Drug Metab Dispos 24: 619-627. (Pubitemid 26170712)
16. Sánchez-Chapula J. 1996. Increase in action potential duration and inhibition of the delayed rectifier outward current IK by berberine in cat ventricular myocytes. Br J Pharmacol 117: 1427-1434. (Pubitemid 126422863)
17. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. 2000. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 97: 1433-1437. (Pubitemid 30118458)
18. Taylor CT, Baird AW. 1995. Berberine inhibition of electrogenic ion transport in rat colon. Br J Pharmacol 116: 2667-2672.
19. Tsai PL, Tsai TH. 2004. Hepatobiliary excretion of berberine. Drug Metab Dispos 32: 405-412.
20. Wu X, Li Q, Xin H, Yu A, Zhong M. 2005. Effects of berberine on the blood concentration of cyclosporine A in renal transplanted recipients: clinical and pharmacokinetics study. Eur J Clin Pharmacol 61: 567-572. (Pubitemid 41414240)
21. Yu HH, Kim KJ, Cha JD et al. 2005. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food 8: 454-461. (Pubitemid 43121896)